"Cannabidiol as a Potential Treatment for Anxiety Disorders

The purpose of the current review is to determine CBD’s potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, 
human experimental, clinical, and epidemiological studies. 





This review emphasizes the potential value and need for further study of CBD in the treatment of anxiety disorders.

Fear and anxiety are adaptive responses essential to coping with threats to survival. Yet excessive or persistent fear may be maladaptive, leading to disability. Symptoms arising from excessive fear and anxiety occur in a number of neuropsychiatric disorders, including generalized anxiety disorder (GAD), panic disorder (PD), post-traumatic stress disorder (PTSD), social anxiety disorder (SAD), and obsessive–compulsive disorder (OCD).

Notably, PTSD and OCD are no longer classified as anxiety disorders in the recent revision of the Diagnostic and Statistical Manual of Mental Disorders, however, excessive anxiety is central to the symptomatology of both disorders. These anxiety-related disorders are associated with a diminished sense of well-being, elevated rates of unemployment and relationship breakdown, and elevated suicide risk

Israeli Researchers Discover How And Why Autism Responds Well To Cannabis

Israeli scientists have discovered the reason why kids with autism 
respond so well to cannabis medications.
It’s because they have lower endogenous cannabinoid levels compared to matched controls.

The study, which was published in the medical journal Molecular Autism, involved analyzing the endocannabinoid serum rates among 93 patients with autism spectrum disorder (ASD) and compared them to controls. The researchers found that the children with ASD have “substantially lower” serum levels of anandamide, a primary endocannabinoid, as well as other compounds.

Israeli scientists have long been in the forefront of autism research, as well as other medical applications of cannabis. This has been a great help to the scientific community at large, who have found it challenging to gain a better understanding of autism among children. This condition spares no one, yet every autistic child is affected in a different way. For this reason, finding standard treatment options has been close to impossible. But cannabis is proving promising for autism.

What is CBCV (Cannabichromevarin)

Cannabichromevarin (CBCV) first came to limelight in 1975 when Thailand researchers at the University of Nagasaki isolated the compound from a cannabis plant. However, not much research has been conducted on the compound since its discovery.

Actually there is not much information to give concerning the properties of CBCV due to the restrictions on marijuana research. However, there is some knowledge that may be used to predict its effect on the human body.

The concentration of CBCV in cannabis plants is much lower compared to cannabidiol (CBD) and tetrahydrocannabinol (THC). CBCV is related to cannabichromene (CBC), a compound that appears in smaller amounts than the two major ones. The chemical structure of CBCV is similar to that of CBC but much shorter. CBCV can rightly be described as a propyl cannabinoid, meaning that its molecular structure contains a propyl chain. The molecular formula for this compound is C19H26O2.

CBC (Cannabichromene)

Cannabichromene (CBC),  is one of the cannabinoids that found in the Cannabis plant and is therefore a phytocannabinoid. 

It bears structural similarity to the other natural cannabinoids, including  tetrahydrocannabinol (THC), tetrahydrocannabivarin (THCV), cannabidiol (CBD), and cannabinol (CBN), among others.

CBC and its derivatives are as abundant as cannabinols in cannabis.It is not scheduled by the Convention on Psychotropic Substances.

Cannabichromene was discovered in 1966 by Gaoni and Mechoulam on one hand and almost simultaneously by Claussen on the other, although since then little research has been carried out on this cannabinoid, with THC and CBD being the protagonists of the majority of subsequent studies. 

However, as we will see below, today there is a growing body of evidence demonstrating the tremendous therapeutic potential of this cannabinoid, especially in combination with other compounds in what is often referred to as an "ensemble effect of cannabinoids".

"ECH announces plans to open first UK medical cannabis clinics"

European Cannabis Holdings (ECH) has announced plans to open The Medical Cannabis Clinics in a step toward aiding patients living with a range of chronic conditions

The clinics, which will open this spring, will be the first in the UK to offer cannabis-based therapy and prescription cannabiniods to patients suffering from chronic pain conditions including arthritis, fibromyalgia, nerve conditions, muscle cramps (spasticity); treating neurological conditions such as epilepsy, multiple sclerosis, Alzheimer’s and Parkinson’s disease; and addressing psychiatric problems such as depression, anxiety and post-traumatic stress disorder (PTSD).

The first clinic will open at The Beeches Consulting Centre in Manchester in March and will be led by Dr David McDowell, a Consultant in Pain Management who issued the first prescription for medical cannabis in December.

Clinics will then open in London across multiple disciplines including neurology and psychiatry in addition to chronic pain, on Harley Street, and in Birmingham later this spring.